KOFU study A cross-sectional web survey study on biologics benefit in view of severe asthma patients
Not Applicable
- Conditions
- asthma
- Registration Number
- JPRN-UMIN000043238
- Lead Sponsor
- AstraZeneca K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 700
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who cannot complete all questions of this survey's questionnaire 2) Patients who answered questions in less than 2 seconds per question in average
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate patients satisfaction, subjective impression for asthma and patients impression for current treatment in severe asthma patients with biologics (BIO) treatment, and severe asthma patients without BIO treatment and previously recommended to use BIO treatment
- Secondary Outcome Measures
Name Time Method